A multi-institutional prospective cohort study of minimal residual
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.7563
WebMay 31, 2023 · Abstract. 7563. Background: Roughly 80% of pts with peripheral T-cell lymphomas (PTCL) respond to CHOP-based therapy but 5-yr survival ranges between 20-40%. The high relapse rate after complete response (CR) suggests more sensitive response assessment, such as minimal residual disease (MRD) testing, could have prognostic or …
DA: 41 PA: 65 MOZ Rank: 76